Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.35 |
| ▸ | FABP7 | O15540 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051474 | 0.88 | KMT2A (0.37) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL10076575 | 0.86 | CASP3 (0.41) | KMT2AEPHX2CASP3PIN1MDM4 | |
| SCHEMBL18949190 | 0.82 | HTR2A (0.31) | — | |
| SCHEMBL768971 | 0.78 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL13007532 | 0.77 | HTR2A (0.34) | — | |
| SCHEMBL23395771 | 0.77 | CASP3 (0.40) | KMT2ACASP3PIN1MDM4TP53 | |
| SCHEMBL21895802 | 0.76 | TLR2 (0.45) | CASP3MDM4TP53 | |
| SCHEMBL27256575 | 0.76 | MDM4 (0.42) | CASP3MDM4TP53 | |
| SCHEMBL22995984 | 0.76 | KMT2A (0.36) | KMT2AEPHX2 | |
| SCHEMBL26761659 | 0.76 | MDM4 (0.38) | CASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4001269-A1 | BENZOISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | Amgen Inc. (US) | 2022-05-25 | — | — | EP | disclosed |